Insmed Q2 ARIKAYCE rev $77.2M (+18%), raises FY guide $295-305M; net loss $244.8M

INSMED Inc

2023-Q2 EPS reported -$2.95 revenue$142,443,000

ARIKAYCE global revenue $77.2M, 18% YoY growth, highest quarterly sales since launch.
Full-year 2023 ARIKAYCE revenue guidance raised to $295-305M from $285-300M.
Net loss $244.8M ($1.78/sh) vs $95.6M loss in Q2 2022; R&D costs rose due to $76.5M acquisition of Adrestia.
Cash, equivalents, marketable securities $918M as of June 30, down from $999M at March 31.
Upcoming catalysts: ARISE topline data Sept 2023; ASPEN Phase 3 data expected Q2 2024; TPIP interim data H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.